| Name | Title | Contact Details |
|---|---|---|
Michaela Murry |
Human Resources Director | Profile |
American Global is a prominent privately held insurance and surety brokerage firm based in Miami, Florida. With over 100 locations worldwide, the company specializes in construction risk management. Their mission focuses on understanding client needs and creating tailored solutions, fostering long-term partnerships to enhance the brokerage experience. The firm offers a wide range of services, including managing complex surety programs, providing consultative insurance solutions, and designing captive finance options. They also create Controlled Insurance Programs (CIPs) and Subcontractor Default Insurance (SDI) programs to help clients minimize costs and manage risks effectively. American Global serves a diverse clientele in the construction industry, including general contractors and construction management firms. The company promotes a culture of innovation and collaboration, encouraging employees to contribute to the future of construction brokerage. American Global has been recognized as one of the "Best Places to Work" by Business Insurance for two consecutive years, reflecting their commitment to employee satisfaction and development.
Autohuset Vestergaard A/S, Personvogne er blandt landets største bilvirksomheder. Vi har autoriseret salg af 11 bilmærker - Volvo, Polestar, Renault, KIA, Ford, Mazda, Dacia, Nissan, Maxus, JAC og BYD. Vi er repræsenteret med 12 filialer - Autohuset Vestergaard beskæftiger cirka 450 medarbejdere og sælger årligt mere end 15.000 nye og brugte biler. Vi er specialister inden for person- og varebiler til private og erhvervsdrivende. Autohuset Vestergaard skræddersyer en løsning, der matcher netop dit behov. Hvad end du ønsker at lease eller eje, så har vi løsningen til dig. Alle vores værksteder er ISO-certificerede og bemandet med top professionelle medarbejdere, der sikrer optimal pleje af din bil, uanset om det gælder service, reparation eller skadearbejde. Hos Autohuset Vestergaard er det vores målsætning, at skabe langsigtede relationer med vores kunder. I vores daglige arbejder bestræber vi os altid på at yde den indsats, der skal til, for at vi opnår yderst tilfredse kunder.
The Badminton World Federation (BWF) is the international governing body of the sport of badminton, recognised by the International Olympic Committee (IOC) and the International Paralympic Committee (IPC). It was originally the International Badminton Federation (IBF) which was founded on 5 July, 1934, before being rechristened the Badminton World Federation in 2006. The purpose and objectives of BWF include regulating, promoting, developing and popularising the sport of badminton throughout the world and organising, conducting and presenting international events at the highest level. The BWFs vision is to make badminton a leading global sport accessible to all – giving every child a chance to play for life. Its mission is to lead and inspire all stakeholders; to deliver entertainment through exciting events to drive fan experience; and to create innovative, impactful and sustainable development initiatives. BWF has its headquarters in Kuala Lumpur, Malaysia, with 194 Member Associations worldwide. Poul-Erik Høyer is the BWF President and Thomas Lund is the BWF Secretary General.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.